Patient characteristics
death, tumor
ONCOLOGY, TUMOR, DISEASE CHARACTERISTIC
We enrolled 26 patients between January 2020 and December 2021, of whom one withdrew their consent during the study. The patient demographics and characteristics are shown in Table Baseline patient demographics and disease characteristics.Abbreviations: CCRT, concurrent chemoradiation therapy; ECOG PS, Eastern Cooperative Oncology Group performance state; EGFR, epidermal growth factor receptor; EGFR‐TKI, epidermal growth factor receptor tyrosine kinase inhibitor; PD‐L1, programmed death ligand 1; TMB, tumor mutation burden.More than half (76.9%, 20/26) of the patients received gefitinib as the first‐line EGFR‐TKI treatment, and 12 (46.2%) received osimertinib as the second‐line treatment before platinum‐based chemotherapy.